Skip to main content
Signal8
Launch Terminal

GERON CORP (GERN)

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Geron Corporation logo

Geron Corporation

NASDAQ:GERNHealthcare
-5.47%$0.8944
AH$0.8901-0.48%vs close
Mkt Cap$574.63M
Float626.73M
O/S642.47M
Vol
$ Vol
RVOL
Inst Own74.2%
SI11.9%
Earnings
Dilution
Geron Corporation logoNASDAQ:GERN$0.8944-5.47%
FormDescription
8-K
8.01,9.01
3
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report
8-K
2.02,9.01
S-8
SEC Filing
10-Q
Quarterly Report
8
4
Statement of Changes in Beneficial Ownership
8-K
5.02,5.07,9.01
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
10-Q
Quarterly Report
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
ARS
SEC Filing
DEFA14A
Additional Proxy Materials
DEF 14A
Definitive Proxy Statement
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
4
Statement of Changes in Beneficial Ownership

1-25 of 1,561

…